Evidence map›Paper›PMID 37269435›Full record

ArticleJournal of computer-aided molecular design2023

Elucidating the potential effects of point mutations on FGFR3 inhibitor resistance via combined molecular dynamics simulation and community network analysis.

Bo Liu, Juntao Ding, Yugang Liu, Jianzhang Wu, Xiaoping Wu, Qian Chen, Wulan Li

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of computer-aided molecular design, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 75% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Bo LiuThe First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
Juntao DingThe First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
Yugang LiuThe First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
Jianzhang WuOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Wenzhou, Zhejiang, 325000, China.
Xiaoping WuInstitute of Tissue Transplantation and Immunology, College of Life Science and Technology, Jinan University, Guangzhou, 510632, China.
Qian ChenFuture Health Laboratory, Innovation Center of Yangtze River Delta, Zhejiang University, Jiaxing, 314102, China. chenqian200709@163.com.
Wulan LiThe First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China. lwlwzmu@163.com.
Zhejiang Lab · CNAffiliated Eye Hospital of Wenzhou Medical College · CNJinan University · CNWenzhou Medical University · CNZhejiang University · CN

Funding

MOE Key Laboratory of Tumor Molecular Biology 50411651-2020-4National Natural Science Foundation of China 81402839National Natural Science Foundation of China 81803580Natural Science Foundation of Zhejiang Province LGF20B020001the Guangdong Basic and Applied Basic Research Foundation 2021A1515011184
6 · The paper itself

Abstract

FGFR3 kinase mutations are associated with a variety of malignancies, but FGFR3 mutant inhibitors have rarely been studied. Furthermore, the mechanism of pan-FGFR inhibitors resistance caused by kinase domain mutations is still unclear. In this study, we try to explain the mechanism of drug resistance to FGFR3 mutation through global analysis and local analysis based on molecular dynamics simulation, binding free energy analysis, umbrella sampling and community network analysis. The results showed that FGFR3 mutations caused a decrease in the affinity between drugs and FGFR3 kinase, which was consistent with the reported experimental results. Possible mechanisms are that mutations affect drug-protein affinity by altering the environment of residues near the hinge region where the protein binds to the drug, or by affecting the A-loop and interfering with the allosteric communication networks. In conclusion, we systematically elucidated the underlying mechanism of pan-FGFR inhibitor resistance caused by FGFR3 mutation based on molecular dynamics simulation strategy, which provided theoretical guidance for the development of FGFR3 mutant kinase inhibitors.

Indexed as

Drug Resistance, NeoplasmNeoplasmsPoint MutationReceptor, Fibroblast Growth Factor, Type 3Community NetworksHumansMolecular Dynamics SimulationMutationProtein Kinase InhibitorsFGFR3 protein, humanProtein Kinase InhibitorsReceptor, Fibroblast Growth Factor, Type 3Allosteric communication networkDrug resistanceFGFR3MD simulationsUmbrella sampling

Identifiers

PMID37269435
OpenAlexW4379207986

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.